Enhanced expression of HIV and SIV vaccine antigens in the structural gene region of live attenuated rubella viral vectors and their incorporation into virions

Vaccine

Volumn 31, Issue 17, 2013, Pages 2119-2125

  Virnik, Konstantin ^a   Ni, Yisheng ^a   Berkower, Ira ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Antigen incorporation; HIV MPER; Live viral vectors; Rubella vaccine strain RA27 3; SIV Gag; Stable expression

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LIVE VACCINE; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS VECTOR;

ANTIGEN EXPRESSION; ARTICLE; GENE INSERTION; GENE STRUCTURE; IMMUNOGENICITY; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RHESUS MONKEY; RUBELLA; VIRION; VIRUS GENOME;

AIDS VACCINES; ANIMALS; CERCOPITHECUS AETHIOPS; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENE EXPRESSION; GENE PRODUCTS, GAG; GENETIC ENGINEERING; GENETIC VECTORS; HIV ANTIGENS; HIV INFECTIONS; HUMANS; MACACA MULATTA; PROMOTER REGIONS, GENETIC; RECOMBINANT PROTEINS; RUBELLA VIRUS; SAIDS VACCINES; SERIAL PASSAGE; VACCINES, ATTENUATED; VERO CELLS; VIRAL STRUCTURAL PROTEINS; VIRION; VIRUS REPLICATION;

EID: 84875851580     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.02.055     Document Type: Article

References (42)

1. Berkower I., Murphy D., Smith C.C., Smith G.E. A predominant group-specific neutralizing epitope of human immunodeficiency virus type 1 maps to residues 342 to 511 of the envelope glycoprotein gp120. J Virol 1991 Nov, 65(11):5983-5990.
2. Thali M., Olshevsky U., Furman C., Gabuzda D., Posner M., Sodroski J. Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody. J Virol 1991 Nov, 65(11):6188-6193.
3. Wu X., Zhou T., Zhu J., Zhang B., Georgiev I., Wang C., et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 2011 Sep 16, 333(6049):1593-1602.
4. Scheid J.F., Mouquet H., Ueberheide B., Diskin R., Klein F., Oliveira T.Y., et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 2011 Sep 16, 333(6049):1633-1637.
5. Phillips R.E., Rowland-Jones S., Nixon D.F., Gotch F.M., Edwards J.P., Ogunlesi A.O., et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 1991 Dec 12, 354(6353):453-459.
6. Barouch D.H., Korber B. HIV-1 vaccine development after STEP. Annu Rev Med 2010, 61:153-167.
7. Bonaldo M.C., Martins M.A., Rudersdorf R., Mudd P.A., Sacha J.B., Piaskowski S.M., et al. Recombinant yellow fever vaccine virus 17D expressing simian immunodeficiency virus SIVmac239 gag induces SIV-specific CD8+ T-cell responses in rhesus macaques. J Virol 2010 Apr, 84(7):3699-3706.
8. Montero M, van Houten NE, Wang X, Scott JK. The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol Mol Biol Rev 2008 Mar;72(1):54-84, table of contents.
9. Shiver J.W., Fu T.M., Chen L., Casimiro D.R., Davies M.E., Evans R.K., et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002 Jan 17, 415(6869):331-335.
10. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., Hendrickson W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998 Jun 18, 393(6686):648-659.
11. Kwong P.D., Doyle M.L., Casper D.J., Cicala C., Leavitt S.A., Majeed S., et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002, 420(Dec (6916)):678-682.
12. Berkower I., Patel C., Ni Y., Virnik K., Xiang Z., Spadaccini A. Targeted deletion in the beta20-beta21 loop of HIV envelope glycoprotein gp120 exposes the CD4 binding site for antibody binding. Virology 2008, 377(Aug (2)):330-338.
13. Saunders K.O., Rudicell R.S., Nabel G.J. The design and evaluation of HIV-1 vaccines. AIDS 2012, 26(Jun (10)):1293-1302.
14. Katz S.L., Kempe C.H., Black F.L., Lepow M.L., Krugman S., Haggerty R.J., et al. Studies on an attenuated measles-virus vaccine. VIII. General summary and evaluation of the results of vaccine. The New England journal of medicine 1960, 263(Jul):180-184.
15. Hilleman M.R., Buynak E.B., Weibel R.E., Stokes J. Live, attenuated rubella-virus vaccine. The New England journal of medicine 1968, 279(Aug (6)):300-303.
16. Watson J.C., Hadler S.C., Dykewicz C.A., Reef S., Phillips L. Measles, mumps, and rubella--vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1998, 47(May (RR-8)):1-57.
17. Baba T.W., Liska V., Khimani A.H., Ray N.B., Dailey P.J., Penninck D., et al. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat Med 1999, 5(Feb (2)):194-203.
18. Rose N.F., Marx P.A., Luckay A., Nixon D.F., Moretto W.J., Donahoe S.M., et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 2001, 106(Sep (5)):539-549.
19. Earl P.L., Wyatt L.S., Montefiori D.C., Bilska M., Woodward R., Markham P.D., et al. Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model. Virology 2002, 294(Mar (2)):270-281.
20. Patterson L.J., Malkevitch N., Venzon D., Pinczewski J., Gomez-Roman V.R., Wang L., et al. Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting. J Virol 2004, 78(Mar (5)):2212-2221.
21. Johnston R.E., Johnson P.R., Connell M.J., Montefiori D.C., West A., Collier M.L., et al. Vaccination of macaques with SIV immunogens delivered by Venezuelan equine encephalitis virus replicon particle vectors followed by a mucosal challenge with SIVsmE660. Vaccine 2005, 23(Oct (42)):4969-4979.
22. Demberg T., Florese R.H., Heath M.J., Larsen K., Kalisz I., Kalyanaraman V.S., et al. A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J Virol 2007, 7(Apr):3414-3427.
23. Robert-Guroff M. Replicating and non-replicating viral vectors for vaccine development. Curr Opin Biotechnol 2007, 18(Dec (6)):546-556.
24. Plotkin S.A., Reef S. Rubella Vaccine. Vaccines 2004, 707-743. Saunders, Philadelphia. 4th ed. S.A. Plotkin, W.A. Orenstein (Eds.).
25. Virnik K., Ni Y., Berkower I. Live attenuated rubella viral vectors stably express HIV and SIV vaccine antigens while reaching high titers. Vaccine 2012, 30(Aug (37)):5453-5458.
26. Tzeng W.P., Frey T.K. Complementation of a deletion in the rubella virus p150 nonstructural protein by the viral capsid protein. J Virol 2003, 77(Sep (17)):9502-9510.
27. Spadaccini A., Virnik K., Ni Y., Prutzman K., Berkower I. Stable expression of a foreign protein by a replication-competent rubella viral vector. Vaccine 2010, 28(Feb (5)):1181-1187.
28. Kujala P., Ahola T., Ehsani N., Auvinen P., Vihinen H., Kaariainen L. Intracellular distribution of rubella virus nonstructural protein P150. J Virol 1999, 73(Sep (9)):7805-7811.
29. Purtscher M., Trkola A., Gruber G., Buchacher A., Predl R., Steindl F., et al. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1994, 10(Dec (12)):1651-1658.
30. Stiegler G., Kunert R., Purtscher M., Wolbank S., Voglauer R., Steindl F., et al. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2001, 17(Dec (18)):1757-1765.
31. Nelson J.D., Brunel F.M., Jensen R., Crooks E.T., Cardoso R.M., Wang M., et al. An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10. J Virol 2007, 81(Apr (8)):4033-4043.
32. Allen T.M., Mothe B.R., Sidney J., Jing P., Dzuris J.L., Liebl M.E., et al. CD8(+) lymphocytes from simian immunodeficiency virus-infected rhesus macaques recognize 14 different epitopes bound by the major histocompatibility complex class I molecule mamu-A*01: implications for vaccine design and testing. J Virol 2001, 75(Jan (2)):738-749.
33. Loffredo J.T., Sidney J., Wojewoda C., Dodds E., Reynolds M.R., Napoe G., et al. Identification of seventeen new simian immunodeficiency virus-derived CD8+ T cell epitopes restricted by the high frequency molecule, Mamu-A*02, and potential escape from CTL recognition. J Immunol 2004, 173(Oct (8)):5064-5076.
34. Sacha J.B., Giraldo-Vela J.P., Buechler M.B., Martins M.A., Maness N.J., Chung C., et al. Gag- and Nef-specific CD4+ T cells recognize and inhibit SIV replication in infected macrophages early after infection. Proc Natl Acad Sci U S A 2009, 106(Jun (24)):9791-9796.
35. Parkman P.D., Phillips P.E., Kirschstein R.L., Meyer H.M. Experimental rubella virus infection in the rhesus monkey. J Immunol 1965, 95(Oct (4)):743-752.
36. Risco C., Carrascosa J.L., Frey T.K. Structural maturation of rubella virus in the Golgi complex. Virology 2003, 312(Aug (2)):261-269.
37. Verkoczy L., Diaz M., Holl T.M., Ouyang Y.B., Bouton-Verville H., Alam S.M., et al. Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance. Proc Natl Acad Sci USA 2010, 107(Jan (1)):181-186.
38. Yao J.S., Strauss E.G., Strauss J.H. Interactions between PE2, E1, and 6K required for assembly of alphaviruses studied with chimeric viruses. J Virol 1996, 70(Nov (11)):7910-7920.
39. Kirnbauer R., Booy F., Cheng N., Lowy D.R., Schiller J.T. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A 1992, 89(Dec (24)):12180-12184.
40. Berzofsky J., Berkower I.J. Immunogenicity and Antigen Structure. Fundamental immunology 2008, 631-683. Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia. 6th ed. W.E. Paul (Ed.).
41. Daniel M.D., Kirchhoff F., Czajak S.C., Sehgal P.K., Desrosiers R.C. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992, 258(Dec (5090)):1938-1941.
42. Hansen S.G., Ford J.C., Lewis M.S., Ventura A.B., Hughes C.M., Coyne-Johnson L., et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011, 473(May (7348)):523-527.